Vitenskapelig artikkel

• Tobias M.P. Hartwich; Seungji Choi; Ayoung Hwang et al. (2026). Integrated mutational landscape analysis of endometrial stromal sarcoma. (ekstern lenke)
• Ingunn Marie Stefansson; Gøril Knutsvik; Jarle Birger Arnes et al. (2025). Loss of androgen receptor expression is associated with aggressive tumor features and reduced survival in breast cancer patients. (ekstern lenke)
• Anna Kristine Myrmel Sæle; Amalie Abrahamsen Svanøe; Cecilie Askeland et al. (2025). Reduced GATA3 expression associates with immuno-metabolic alterations and aggressive features in breast cancer. (ekstern lenke)
• Hannah Ni Bhriain; Jone Trovik; Elisabeth Wik et al. (2009). Plasma calprotectin concentrations in women with endometrial carcinoma. (ekstern lenke)
• Elisabeth Wik; Jone Trovik; Ole-Erik Iversen et al. (2009). Deoxyribonucleic acid ploidy in endometrial carcinoma: a reproducible and valid prognostic marker in a routine diagnostic setting. (ekstern lenke)
• Monica Mannelqvist; Ingunn Marie Stefansson; Geir Bredholt et al. (2011). Gene Expression Patterns Related to Vascular Invasion and Aggressive Features in Endometrial Cancer. (ekstern lenke)
• Tor Audun Klingen; Ying Chen; Pål Suhrke et al. (2013). Expression of thyroid transcription factor-1 is associated with a basal-like phenotype in breast carcinomas. (ekstern lenke)
• Ingunn Marie Stefansson; Helga Salvesen; Lars A. Akslen (2004). Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. (ekstern lenke)
• Ingunn Marie Stefansson; Helga Salvesen; Lars A. Akslen (2004). Prognostic impact of histological grade and vascular invasion compared with tumor cell proliferation in endometrial carcinoma of endometrioid type. (ekstern lenke)
• Sigmund Ytre-Hauge; Jenny Hild Aase Husby; Inger Johanne Magnussen et al. (2015). Preoperative tumor size at MRI predicts deep myometrial invasion, lymph node metastases, and patient outcome in endometrial carcinomas. (ekstern lenke)
• WD Foulkes; JS Brunet; Ingunn Marie Stefansson et al. (2004). The prognostic implication of the basal-like (cyclin E-high/p27(low)/p53(+)/glomeruloid-microvascular-proliferation(+)) phenotype of BRCA1-related breast cancer. (ekstern lenke)
• Camilla Krakstad; Jone Trovik; Elisabeth Wik et al. (2012). Loss of GPER identifies new targets for therapy among a subgroup of ER alpha-positive endometrial cancer patients with poor outcome. (ekstern lenke)
• Lise Martine Ingebriktsen; Amalie Abrahamsen Svanøe; Anna Kristine Myrmel Sæle et al. (2024). Age-Related Clusters and Favorable Immune Phenotypes in Breast Cancer of the Young Patients. (ekstern lenke)
• Elisabeth Wik; Sura Mohammed Aziz; Heidrun Vethe et al. (2022). Neurogenesis and angiogenesis are associated features of aggressive breast cancer. (ekstern lenke)
• Karin Collett; Geir Egil Eide; Jarle Arnes et al. (2006). Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. (ekstern lenke)
• ND Macdonald; Helga Salvesen; A Ryan et al. (2004). Molecular differences between RER+ and RER- sporadic endometrial carcinomas in a large population-based series. (ekstern lenke)
• Christine Gjerdrum; Crina Elena Tiron; Torill Høiby et al. (2010). Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. (ekstern lenke)
• Ingfrid S. Haldorsen; Ingunn Stefansson; Renate Grüner et al. (2014). Increased microvascular proliferation is negatively correlated to tumour blood flow and is associated with unfavourable outcome in endometrial carcinomas. (ekstern lenke)
• Ingeborg Engelsen; Ingunn Marie Stefansson; Lars A. Akslen et al. (2006). Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas. (ekstern lenke)
• Gøril Knutsvik; Ingunn Stefansson; Sura Mohammed Aziz et al. (2014). Evaluation of Ki67 expression across distinct categories of breast cancer specimens: A Population-based study of matched surgical specimens, core needle biopsies and tissue microarrays. (ekstern lenke)
• William J. Gibson; Erling Andre Høivik; Mari Kyllesø Halle et al. (2016). The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. (ekstern lenke)
• Tina Fonnes; Elin Strand; Kristine Eldevik Fasmer et al. (2020). Near-Infrared Fluorescent Imaging for Monitoring of Treatment Response in Endometrial Carcinoma Patient-Derived Xenograft Models. (ekstern lenke)
• Amit Dutt; Helga Salvesen; Tzu-Hsiu Chent et al. (2008). Drug-sensitive FGFR2 mutations in endometrial carcinoma. (ekstern lenke)
• Gøril Knutsvik; Karin Collett; Jarle Arnes et al. (2016). QSOX1 expression is associated with aggressive tumor features and reduced survival in breast carcinomas. (ekstern lenke)
• Monica Mannelqvist; Ingunn Marie Stefansson; Helga Birgitte Salvesen et al. (2009). Importance of tumour cell invasion in blood and lymphatic vasculature among patients with endometrial carcinoma. (ekstern lenke)
• Katharina Bischof; Stian Knappskog; Sigrun Margrethe Hjelle et al. (2019). Influence of p53 isoform expression on survival in high-grade serous ovarian cancers. (ekstern lenke)
• Ingeborg Margrethe Bachmann; Ole Johan Halvorsen; Karin Collett et al. (2006). EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. (ekstern lenke)
• Helga Salvesen; Rajiv Kumar; Ingunn Marie Stefansson et al. (2005). Low frequency of BRAF and CDKN2A mutations in endometrial cancer. (ekstern lenke)
• Hawa Nalwoga; Jarle Arnes; Ingunn Marie Stefansson et al. (2011). Vascular proliferation is increased in basal-like breast cancer. (ekstern lenke)
• Cecilie Fredvik Torkildsen; Liv Cecilie Vestrheim Thomsen; Ragnar Sande et al. (2023). Molecular and phenotypic characteristics influencing the degree of cytoreduction in high-grade serous ovarian carcinomas. (ekstern lenke)
• Margrethe Raspotnig; Mette Haugen; Maria Thorsteinsdottir et al. (2017). Cerebellar degeneration-related proteins 2 and 2-like are present in ovarian cancer in patients with and without Yo antibodies. (ekstern lenke)
• Ingunn Stefansson; Maria B Ræder; Elisabeth Wik et al. (2015). Increased angiogenesis is associated with a 32-gene expression signature and 6p21 amplification in aggressive endometrial cancer. (ekstern lenke)
• Ingeborg Bøe Engelsen; Monica Mannelqvist; Ingunn Marie Stefansson et al. (2008). Low BMI-1 expression is associated with an activated BMI-1-driven signature, vascular invasion, and hormone receptor loss in endometrial carcinoma. (ekstern lenke)
• Karen Klepsland Mauland; Elisabeth Wik; Erling Andre Høivik et al. (2016). Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival. (ekstern lenke)
• Anna Berg; Erling Andre Høivik; Siv Mjøs et al. (2015). Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients. (ekstern lenke)
• Geir Bredholt; Monica Mannelqvist; Ingunn Stefansson et al. (2015). Tumor necrosis is an important hallmark of aggressive endometrial cancer and associates with hypoxia, angiogenesis and inflammation responses. (ekstern lenke)
• Camilla Krakstad; Ingvild Løberg Tangen; Erling Andre Høivik et al. (2015). ATAD2 overexpression links to enrichment of B-MYBtranslational signatures and development of aggressive endometrial carcinoma. (ekstern lenke)
• Jarle Arnes; Ingunn Marie Stefansson; Oddbjørn Straume et al. (2012). Vascular proliferation is a prognostic factor in breast cancer. (ekstern lenke)
• Helga Birgitte Salvesen; Scott L. Carter; Monica Mannelqvist et al. (2009). Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. (ekstern lenke)
• Julie Andrea Dybvik; Kristine Eldevik Fasmer; Sigmund Ytre-Hauge et al. (2022). MRI-assessed tumor-free distance to serosa predicts deep myometrial invasion and poor outcome in endometrial cancer. (ekstern lenke)
• Ingfrid S. Haldorsen; Renate Grüner; Jenny Hild Aase Husby et al. (2013). Dynamic contrast-enhanced MRI in endometrial carcinoma identifies patients at increased risk of recurrence. (ekstern lenke)
• WD Foulkes; Ingunn Marie Stefansson; PO Chappuis et al. (2003). Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. (ekstern lenke)
• Helga B. Salvesen; Mine G Gulluoglu; Ingunn Marie Stefansson et al. (2003). Significance of CD 105 expression for tumour angiogenesis and prognosis in endometrial carcinomas. (ekstern lenke)
• Mari Kyllesø Halle; Ingvild Løberg Tangen; Hege Fredriksen Berg et al. (2017). HER2 expression patterns in paired primary and metastatic endometrial cancer lesions. (ekstern lenke)
• Anna Berg; Ankush Gulati; Sigmund Ytre-Hauge et al. (2017). Preoperative imaging markers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and low grade cancers. (ekstern lenke)
• Nicole C.M. Visser; Henrica Maria Johanna Werner; Camilla Krakstad et al. (2017). Type of vascular invasion in association with progress of endometrial cancer. (ekstern lenke)
• Cecilie Askeland; Elisabeth Wik; Kenneth Finne et al. (2020). Stathmin expression associates with vascular and immune responses in aggressive breast cancer subgroups. (ekstern lenke)
• Elisabeth Wik; Even Birkeland; Jone Trovik et al. (2013). High phospho-stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition. (ekstern lenke)
• Elisabeth Wik; Maria B Ræder; Camilla Krakstad et al. (2013). Lack of estrogen receptor-alpha is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma. (ekstern lenke)
• Kristi Krüger; Laxmi Silwal-Pandit; Elisabeth Wik et al. (2021). Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer. (ekstern lenke)
• Monica Mannelqvist; Elisabeth Wik; Ingunn Stefansson et al. (2014). An 18-Gene signature for vascular invasion is associated with aggressive features and reduced survival in breast cancer. (ekstern lenke)
• Cecilie Fredvik Torkildsen; Marie Austdal; Anders Hagen Jarmund et al. (2024). New immune phenotypes for treatment response in high-grade serous ovarian carcinoma patients. (ekstern lenke)
• Jone Trovik; Elisabeth Wik; Henrica Maria Johanna Werner et al. (2013). Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial. (ekstern lenke)
• Ingunn Marie Stefansson; Helga Salvesen; Lars A. Akslen (2006). Vascular proliferation is important for clinical progress of endometrial cancer. (ekstern lenke)
• Helga Salvesen; Ingunn Marie Stefansson; EI Kretzschmar et al. (2004). Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression. (ekstern lenke)
• Karen Klepsland Mauland; Jone Trovik; Elisabeth Wik et al. (2011). High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer. (ekstern lenke)
• Karin Collett; Ingunn Marie Stefansson; Johan Eide et al. (2005). A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. (ekstern lenke)
• Ingrid Vandenput; Jone Trovik; Karin Leunen et al. (2011). Evolution in endometrial cancer evidence from an immunohistochemical study. (ekstern lenke)
• Maria B Ræder; Even Birkeland; Jone Trovik et al. (2013). Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers. (ekstern lenke)
• Ingvild Kathrin Lokøy; Inga Sofie Bakken; Elisabeth Wik et al. (2024). Brystkreft hos menn – histopatologi og biomarkører. (ekstern lenke)
• Katharina Bischof; Stian Knappskog; Ingunn Stefansson et al. (2018). High expression of the p53 isoform ? is associated with reduced progression-free survival in uterine serous carcinoma. (ekstern lenke)
• Sanne Vermorgen; Thijs Gelton; Peter Bult et al. (2023). Endometrial Pipelle Biopsy Computer-Aided Diagnosis: A Feasibility Study. (ekstern lenke)
• Sigmund Ytre-Hauge; Morteza Esmaeili; Torill Eidhammer Sjøbakk et al. (2017). In vivo MR spectroscopy predicts high tumor grade in endometrial cancer. (ekstern lenke)
• Kristi Krüger; Ingunn Marie Stefansson; Karin Collett et al. (2012). Microvessel proliferation by co-expression of endothelial nestin and Ki-67 is associated with a basal-like phenotype and aggressive features in breast cancer. (ekstern lenke)
• Lise Martine Ingebriktsen; Rasmus Olai Collett Humlevik; Amalie Abrahamsen Svanøe et al. (2024). Elevated expression of Aurora-A/AURKA in breast cancer associates with younger age and aggressive features. (ekstern lenke)
• Amalie Abrahamsen Svanøe; Rasmus Olai Collett Humlevik; Gøril Knutsvik et al. (2024). Age-related phenotypes in breast cancer: A population-based study. (ekstern lenke)
• Ingunn Marie Stefansson; Helga Salvesen; Lars A. Akslen (2006). Loss of p63 and cytokeratin 5/6 expression is associated with more aggressive tumors in endometrial carcinoma patients. (ekstern lenke)
• Elisabeth Wik; Jone Trovik; Kanthida Kusonmano et al. (2014). Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations. (ekstern lenke)
• Ingeborg Bøe Engelsen; Ingunn Marie Stefansson; Rameen Beroukhim et al. (2008). HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas. (ekstern lenke)
• Tor Audun Klingen; Ying Chen; Ingunn Stefansson et al. (2016). Tumour cell invasion into blood vessels is significantly related to breast cancer subtypes and decreased survival. (ekstern lenke)
• Monica Mannelqvist; Ingunn Marie Stefansson; Elisabeth Wik et al. (2012). Lipocalin 2 expression is associated with aggressive features of endometrial cancer. (ekstern lenke)
• Hilde Renate Haugen Engerud; Ingvild Løberg Tangen; Ansgar Berg et al. (2014). High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for HSP90 inhibitors. (ekstern lenke)
• Ingunn Marie Stefansson; Lars A. Akslen; N MacDonald et al. (2002). Loss of hMSH2 and hMSH6 expression is frequent in sporadic endometrial carcinomas with microsatellite instability: a population-based study. (ekstern lenke)
• Kristi Krüger; Elisabeth Wik; Gøril Knutsvik et al. (2017). Expression of Nestin associates with BRCA1 mutations, a basal-like phenotype and aggressive breast cancer. (ekstern lenke)
• Hege Fredriksen Berg; Marta Espevold Hjelmeland; Hilde Eide Lien et al. (2021). Patient-derived organoids reflect the genetic profile of endometrial tumors and predict patient prognosis. (ekstern lenke)
• Helga B. Salvesen; Ingunn Marie Stefansson; May Britt Kalvenes et al. (2002). Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma. (ekstern lenke)
• Jone Trovik; Elisabeth Wik; Ingunn Marie Stefansson et al. (2011). Stathmin Overexpression Identifies High-Risk Patients and Lymph Node Metastasis in Endometrial Cancer. (ekstern lenke)

Rettelse i tidsskrift

• Hege Fredriksen Berg; Marta Espevold Hjelmeland; Hilde Eide Lien et al. (2021). Author Correction: Patient-derived organoids reflect the genetic profile of endometrial tumors and predict patient prognosis (Communications Medicine, (2021), 1, 1, (20), 10.1038/s43856-021-00019-x). (ekstern lenke)

Doktorgradsavhandling

• Ingunn Marie Stefansson (2005). Biologic and prognostic markers of endometrial carcinoma. (ekstern lenke)

Konferanseposter

• Monica Mannelqvist; Trond Hellem Bø; Geir Bredholt et al. (2007). Patterns of gene expression related to vascular invasion and aggressive features in endometrial cancer. (ekstern lenke)
• Monica Mannelqvist; Trond Hellem Bø; Geir Bredholt et al. (2007). Patterns of gene expression related to vascular invasion and aggressive features in endometrial cancer. (ekstern lenke)
• Helga Salvesen; Trond Hellem Bø; Ingunn Marie Stefansson et al. (2006). Gene expression profiles identify an aggressive phenotype in endometrial carcinoma. (ekstern lenke)
• Jone Trovik; Elisabeth Wik; Ingunn Marie Stefansson et al. (2009). Stathmin is superior to AKT and Phospho-AKT staining to detect PI3Kinase activation and aggressive endometrial cancer. (ekstern lenke)

Konferanseabstrakt

• Ingunn Marie Stefansson; M Mannelquist; HB Salvesen et al. (2010). Prognostic importance of vascular proliferation and tumor cell invasion in blood and lymphatic vessels in endometrial carcinoma. (ekstern lenke)
• Gøril Knutsvik; Ingunn Marie Stefansson; Karin Collett et al. (2013). Proliferation markers PHH3, Ki67 and mitotic count all show significant associations with features of aggressive breast carcinomas and reduced survival. (ekstern lenke)
• Gøril Knutsvik; Ingunn Marie Stefansson; Karin Collett et al. (2013). Proliferation markers PHH3, Ki67 and Mimtotic count all show significant associations with features of aggressive breast carcinomas and reduced survival. (ekstern lenke)
• Elisabeth Wik; Maria Rader; Camilla Krakstad et al. (2012). Estrogen receptor a loss in endometrial carcinoma is associated with epithelial-to-mesenchymal transition and a potential for PI3Kinase inhibition. (ekstern lenke)
• Gøril Knutsvik; Ingunn Marie Stefansson; Karin Collett et al. (2012). Prognostic impact of proliferation markers Ki-67, PHH3 and mitotic count in breast carcinomas. (ekstern lenke)
• Crina Elena Tiron; Christine Gjerdrum; Torill Høiby et al. (2011). Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. (ekstern lenke)

Leserbrev

• Jone Trovik; Elisabeth Wik; Ingunn Marie Stefansson et al. (2010). Stathmin is superior to AKT and phospho-AKT staining for the detection of phosphoinositide 3-kinase activation and aggressive endometrial cancer. (ekstern lenke)

Se en fullstendig oversikt over publikasjoner i NVA.